Have your own idea? Try our Stock Screener
Argentinian (MERVAL) Healthcare Sector Analysis
UpdatedAug 17, 2026
DataAggregated Company Financials
Companies1
- 7D1.3%
- 3M-2.2%
- 1Y21.0%
- YTD-22.1%
In the last week, the Healthcare industry is up 1.3%, with Laboratorios RichmondC.I.F up 1.3%. This means that the industry has gained 21% over the past year.
Sector Valuation and Performance
Has the Argentinian Healthcare Sector valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Mon, 17 Aug 2026 | AR$125.6b | AR$114.0b | AR$13.0b | 9.6x | 9.6x | 1.1x |
| Wed, 15 Jul 2026 | AR$126.0b | AR$119.6b | AR$16.1b | 7.7x | 7.8x | 1.1x |
| Fri, 12 Jun 2026 | AR$128.8b | AR$119.6b | AR$16.1b | 8.2x | 8x | 1.1x |
| Sun, 10 May 2026 | AR$130.0b | AR$126.7b | AR$2.4b | 54.7x | 54.1x | 1x |
| Tue, 07 Apr 2026 | AR$143.2b | AR$130.8b | -AR$1,946,644,487.00 | 56.8x | -73.6x | 1.1x |
| Thu, 05 Mar 2026 | AR$139.5b | AR$107.5b | -AR$10,024,883,532.00 | n/a | -13.9x | 1.3x |
| Sat, 31 Jan 2026 | AR$177.4b | AR$107.5b | -AR$10,024,883,532.00 | n/a | -17.7x | 1.7x |
| Mon, 29 Dec 2025 | AR$168.3b | AR$108.5b | -AR$8,970,776,885.00 | n/a | -18.8x | 1.6x |
| Wed, 26 Nov 2025 | AR$156.9b | AR$108.5b | -AR$8,970,776,885.00 | n/a | -17.5x | 1.4x |
| Fri, 24 Oct 2025 | AR$98.0b | AR$103.2b | AR$8.2b | 8.4x | 11.9x | 0.9x |
| Sun, 21 Sep 2025 | AR$84.8b | AR$104.5b | AR$9.0b | 6.8x | 9.4x | 0.8x |
| Tue, 19 Aug 2025 | AR$112.1b | AR$104.5b | AR$9.0b | 8.9x | 12.4x | 1.1x |
| Thu, 17 Jul 2025 | AR$122.0b | AR$102.7b | AR$16.3b | 6.1x | 7.5x | 1.2x |
| Sat, 14 Jun 2025 | AR$130.8b | AR$104.7b | AR$17.4b | 6.2x | 7.5x | 1.2x |
| Mon, 12 May 2025 | AR$119.0b | AR$100.1b | AR$22.4b | 4.8x | 5.3x | 1.2x |
| Wed, 09 Apr 2025 | AR$120.1b | AR$97.1b | AR$23.7b | 4.8x | 5.1x | 1.2x |
| Fri, 07 Mar 2025 | AR$146.1b | AR$42.6b | AR$18.2b | 6.4x | 8x | 3.4x |
| Sun, 02 Feb 2025 | AR$138.1b | AR$42.6b | AR$18.2b | 6.3x | 7.6x | 3.2x |
| Tue, 31 Dec 2024 | AR$142.6b | AR$42.6b | AR$18.2b | 6.8x | 7.8x | 3.3x |
| Thu, 28 Nov 2024 | AR$151.2b | AR$42.6b | AR$18.2b | 6.4x | 8.3x | 3.5x |
| Sat, 26 Oct 2024 | AR$104.7b | AR$40.7b | AR$4.6b | 16.9x | 23x | 2.6x |
| Mon, 23 Sep 2024 | AR$77.6b | AR$40.7b | AR$4.6b | 12.8x | 17x | 1.9x |
| Wed, 21 Aug 2024 | AR$86.7b | AR$52.7b | AR$2.3b | 33.9x | 38.4x | 1.6x |
| Fri, 19 Jul 2024 | AR$77.9b | AR$41.1b | -AR$3,264,658,797.00 | 4.5x | -23.9x | 1.9x |
| Sun, 16 Jun 2024 | AR$85.6b | AR$41.1b | -AR$3,264,658,797.00 | 4.9x | -26.2x | 2.1x |
| Tue, 14 May 2024 | AR$75.2b | AR$43.6b | -AR$10,287,966,966.00 | 9.2x | -7.3x | 1.7x |
| Thu, 11 Apr 2024 | AR$81.8b | AR$40.2b | -AR$10,767,928,257.00 | 54.9x | -7.6x | 2x |
| Sat, 09 Mar 2024 | AR$69.9b | AR$9.6b | -AR$4,702,241,388.00 | 45.2x | -14.9x | 7.2x |
| Mon, 05 Feb 2024 | AR$96.6b | AR$10.3b | -AR$4,704,193,685.00 | 58.1x | -20.5x | 9.3x |
| Wed, 03 Jan 2024 | AR$57.5b | AR$10.3b | -AR$4,704,193,685.00 | 33.4x | -12.2x | 5.6x |
| Fri, 01 Dec 2023 | AR$56.4b | AR$10.3b | -AR$4,704,193,685.00 | 31x | -12x | 5.4x |
| Sun, 29 Oct 2023 | AR$58.0b | AR$13.0b | -AR$2,496,856,221.00 | n/a | -23.2x | 4.4x |
| Tue, 26 Sep 2023 | AR$43.3b | AR$13.0b | -AR$2,496,856,221.00 | n/a | -17.3x | 3.3x |
| Thu, 24 Aug 2023 | AR$47.8b | AR$18.8b | -AR$150,001,147.00 | 15.3x | -318.8x | 2.5x |
Price to Earnings Ratio
-318.8x
Current Industry PE
- There is only one company in the Argentinean Healthcare industry, so there is insufficient data to make an industry-wide assessment of both the PE and PS ratio.
Past Earnings Growth
- Total earnings for the Healthcare industry have gone up over the last three years, and the industry is now profitable. Revenues have grown 82% per year.
- This means that more sales are being generated by the industry overall, and subsequently profits are increasing too.
Industry Trends
Which industries have driven the changes within the Argentinian Healthcare sector?
| AR Market | -2.77% | |
| Healthcare | 1.30% | |
| Pharma | 1.30% | |
Industry PE
- Investors are most optimistic about the Pharma industry which is trading above its 3-year average PE ratio.
- It looks like they are confident that earnings will grow faster in the future than they have historically.
- Investors are most pessimistic about the Pharma industry, although it looks like investor sentiment has improved given that it's trading above its 3-year average.
Forecasted GrowthThere is insufficient data on the sub-industries of this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| RICH Laboratorios RichmondC.I.F | AR$1.56k | 1.3% +AR$1.6b | 21.0% | PE9.6x |